Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 20, 2014, 118 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $277.00 to $8,954,563.40.

Highlighted Stocks Traded by Insiders:

Investment Technology Group (ITG) - FREE Research Report

Meitz David, who is Managing Director at Investment Technology Group, sold 1,200 shares at $20.00 on Nov. 20, 2014. Following this transaction, the Managing Director owned 96,877 shares meaning that the stake was reduced by 1.22% with the 1,200-share transaction.

The shares most recently traded at $19.76, down $0.24, or 1.21% since the insider transaction. Historical insider transactions for Investment Technology Group go as follows:

  • 4-Week # shares bought: 7,000
  • 4-Week # shares sold: 5,500
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 10,500
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 25,500

The average volume for Investment Technology Group has been 250,600 shares per day over the past 30 days. Investment Technology Group has a market cap of $688.5 million and is part of the financial sector and financial services industry. Shares are down 3.26% year-to-date as of the close of trading on Thursday.

Investment Technology Group, Inc. operates as an independent research and execution broker in the United States, Canada, Europe, and the Asia Pacific region. The company has a P/E ratio of 15.2. Currently, there is 1 analyst who rates Investment Technology Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITG - FREE

TheStreet Quant Ratings

rates Investment Technology Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

Investment Technology Group Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Codexis (CDXS) - FREE Research Report

Yang Patrick Y, who is Director at Codexis, bought 20,000 shares at $2.35 on Nov. 20, 2014. Following this transaction, the Director owned 229,515 shares meaning that the stake was boosted by 9.55% with the 20,000-share transaction.

The shares most recently traded at $2.40, up $0.05, or 2.08% since the insider transaction. Historical insider transactions for Codexis go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 80,000

The average volume for Codexis has been 102,300 shares per day over the past 30 days. Codexis has a market cap of $92.1 million and is part of the health care sector and drugs industry. Shares are up 71.43% year-to-date as of the close of trading on Thursday.

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. Currently, there are no analysts who rate Codexis a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CDXS - FREE

TheStreet Quant Ratings

rates Codexis as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

Codexis Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Arqule (ARQL) - FREE Research Report

Pucci Paolo, who is Chief Executive Officer at Arqule, bought 5,000 shares at $1.26 on Nov. 20, 2014. Following this transaction, the Chief Executive Officer owned 247,280 shares meaning that the stake was boosted by 2.06% with the 5,000-share transaction.

The shares most recently traded at $1.28, up $0.02, or 1.59% since the insider transaction. Historical insider transactions for Arqule go as follows:

  • 4-Week # shares bought: 58,500
  • 12-Week # shares bought: 63,500
  • 24-Week # shares bought: 63,500

The average volume for Arqule has been 264,000 shares per day over the past 30 days. Arqule has a market cap of $80.3 million and is part of the health care sector and drugs industry. Shares are down 40.47% year-to-date as of the close of trading on Thursday.

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Currently, there is 1 analyst who rates Arqule a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARQL - FREE

TheStreet Quant Ratings

rates Arqule as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Arqule Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null